Transverse Myelitis Trial, Recruiting NCT06502015 Sponsor: Tongji Hospital Condition: Transverse Myelitis
Back to Transverse Myelitis

Transverse Myelitis Trial, Recruiting

NCT06502015
Recruiting Not Applicable

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

  • People who have been diagnosed with certain inflammatory conditions affecting the nervous system, including: Neuromyelitis Optica Spectrum Disorder (NMOSD), Myasthenia Gravis (MG), Chronic Inflammatory Demyelinating Polyradiculoneuropathy (CIDP), Idiopathic Inflammatory Myopathy (IIM), Multiple Sclerosis (MS), Autoimmune Encephalitis (AE), Myelin Oligodendrocyte Glycoprotein Antibody-Associated Disease (MOGAD), or similar conditions (confirm with trial site)
  • Healthy individuals who are a similar age and sex to patients in the study may also be eligible to participate

Who may not be able to join:

  • People who have a known history of a condition where the immune system does not work properly from birth or that was acquired over time
  • People who currently have a severe infection affecting the brain, spinal cord, lungs, or other parts of the body
  • People whose nervous system symptoms are caused by other underlying conditions such as vasculitis, lupus, or Sjögren's syndrome, rather than the conditions listed above
  • People who have vascular diseases (such as stroke or bleeding in the brain), inherited metabolic disorders, tumors, or toxic-related diseases affecting the nervous system
  • Women who are currently pregnant or breastfeeding

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 28 July 2026
This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.

Contact this trial

Principal Investigator: Dai-shi Tian, MD, Tongji Hospital

Phone: 86-27-83663337

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Not Applicable
Sponsor
Tongji Hospital
Registry
ClinicalTrials.gov
Start date
31 July 2024
Est. completion
1 July 2027

Where this trial is recruiting

🇨🇳 China

Primary endpoints

All-cause mortality

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 28 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov